Not Yet RecruitingEarly Phase 1

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

United States44 participantsStarted 2026-12-01

Plain-language summary

The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Abdominal aortic aneurysm (AAA) requiring open surgical repair
✓. Age \> 18
✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

✕. Prior use of a PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) within 6 months of the baseline visit
✕. LDL-C \< 40 mg/dL (within 3 months of baseline visit)
✕. Known allergy to PCSK9 inhibitor
✕. Aortic dissection
✕. Vascular connective tissue disorders
✕. Type I-III or V Thoraco-abdominal Aortic Aneurysm
✕. Vasculitis or inflammatory aneurysm
✕. Pregnant or lactating women

What they're measuring

Interleukin (IL)-6 in myeloid derived monocytes/macrophages from in AAA tissue

Timeframe: AAA Repair (Week 5)

Trial details

NCT IDNCT06081153

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-01-15

Contact for this trial

Scott Damrauer, MD

215-615-1698 damrauer@upenn.edu

View on ClinicalTrials.gov More Abdominal Aortic Aneurysm trials